More rebates in Italy threaten profitability of pure biotech firms like Amgen and Celgene
20 October 2011
Francesca Bruce
Please Login to read the full article.
20 October 2011
Francesca Bruce
Please Login to read the full article.
RELATED CONTENT
NEWS
- "Needless" generics law compounds untenable situation in Italy, says Assobiotec
- EFPIA's Bergstrom predicts industry will pay for empty promises of Greek reform
- Stockwatch: Consumerise, genericise, and buy back in anger – Q2 earnings
- Further rebates drive Greek pharma to brink
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
FEATURES
- Piramal: regulatory overhaul would help India tackle disease challenges
- Merck BioVentures: where biosimilars make a difference
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
